Latest News

© LASZLO - © LASZLO - stock.adobe.com.
FDA Votes in Favor of Potential Myeloma Therapy Following Positive Results of Phase III Clinical Trial

March 18th 2024

Abecma (idecabtagene vicleucel) demonstrated a favorable benefit/risk profile for patients based on results from the pivotal Phase III KarMMa-3 study.

Image credit: Dzmitry | stock.adobe.com
An Examination of the Use of Patient Recruitment and Retention Tactics for Global Studies

March 18th 2024

Image credit: LASZLO | stock.adobe.com
Phase III Trial Data Show Meaningful Survival Improvements with Jemperli Combinations for Endometrial Cancer

March 18th 2024

Ethical Considerations for Collecting and Analyzing Patient Data with New Technologies
Ethical Considerations for Collecting and Analyzing Patient Data with New Technologies

March 15th 2024

Image credit: ibreakstock | stock.adobe.com
Phase III KEYNOTE-A18 Trial Data Show Keytruda Plus Chemoradiotherapy Improves Overall Survival in High-Risk Cervical Cancer

March 15th 2024

Conference Coverage

View All
SCOPE 2024: YPrime CEO, Jim Corrigan Speaks About the Company and Addressing Uncertainty in Clinical Trials
SCOPE 2024: YPrime CEO, Jim Corrigan Speaks About the Company and Addressing Uncertainty in Clinical Trials

February 19th 2024

SCOPE 2024: Alex Deyle of Flatiron Health Discusses RWD in Clinical Trials
SCOPE 2024: Alex Deyle of Flatiron Health Discusses RWD in Clinical Trials

February 14th 2024

SCOPE 2024: Steve Young of CluePoints Discusses RBQM and Key Risk Indicators
SCOPE 2024: Steve Young of CluePoints Discusses RBQM and Key Risk Indicators

February 13th 2024

SCOPE 2024: Todd Everhart of Signant Health Discusses DCTs and Site Burden
SCOPE 2024: Todd Everhart of Signant Health Discusses DCTs and Site Burden

February 13th 2024

Latest Videos
Podcasts
© Alex from the Rock - © Alex from the Rock - stock.adobe.com
Rinol Alaj, Jaclyn Patterson, Applied Clincial Trials Podcast

All News

© 2024 MJH Life Sciences

All rights reserved.